0001140361-24-009029.txt : 20240222 0001140361-24-009029.hdr.sgml : 20240222 20240222160645 ACCESSION NUMBER: 0001140361-24-009029 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240220 FILED AS OF DATE: 20240222 DATE AS OF CHANGE: 20240222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SIEGAL JONATHAN CENTRAL INDEX KEY: 0001916145 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35280 FILM NUMBER: 24664718 MAIL ADDRESS: STREET 1: C/O VERICEL CORPORATION STREET 2: 64 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vericel Corp CENTRAL INDEX KEY: 0000887359 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943096597 STATE OF INCORPORATION: MI FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 7349305555 MAIL ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC DATE OF NAME CHANGE: 19960428 4 1 form4.xml FORM 4 X0508 4 2024-02-20 0000887359 Vericel Corp VCEL 0001916145 SIEGAL JONATHAN 64 SIDNEY STREET CAMBRIDGE MA 02139 true Principal Accounting Officer false Common Stock 2024-02-20 4 M 0 2500 0 A 3900 D Common Stock 2024-02-20 4 F 0 1117 49.5 D 2783 D Common Stock 2024-02-20 4 M 0 420 0 A 3203 D Common Stock 2024-02-20 4 F 0 169 49.5 D 3034 D Restricted Stock Unit 2024-02-20 4 M 0 2500 A Common Stock 2500 7500 D Restricted Stock Unit 2024-02-20 4 M 0 420 A Common Stock 420 840 D The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 17, 2023. The remaining RSUs will vest in annual installments on February 17, 2025, February 17, 2026, and February 17, 2027, respectively. These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2025, and February 18, 2026, respectively. Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. No expiration date for this type of award. The Fair Market Value of the vested derivative securities is $49.50 per share. /s/ Sean Flynn, as Attorney-in-Fact for Jonathan Siegal 2024-02-22